Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Trial ID or NCT#
NCT03859700
Status
Purpose
Open-label, follow-up study for subjects who completed the EPITOPE study.
Official Title
EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children
Eligibility Criteria
Ages Eligible for Study: 2 Years to 5 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * completion of the EPITOPE study
Exclusion Criteria:
- * Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back or arms with no intact zones to apply the Viaskin patches.* Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma
Investigator(s)
Sayantani Sindher
Allergist,
Immunologist
Clinical Associate Professor, Medicine
Clinical Associate Professor, Pediatrics - Allergy and Clinical Immunology
View on ClinicalTrials.gov